Rep. Josh Gottheimer Purchases Shares of Natera, Inc. (NASDAQ:NTRA)

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Natera, Inc. NASDAQ: NTRA. In a filing disclosed on December 05th, the Representative disclosed that they had bought between $1,001 and $15,000 in Natera stock on November 20th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Regeneron Pharmaceuticals NASDAQ: REGN on 11/29/2024.
• Purchased $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 11/27/2024.
• Sold $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 11/27/2024.
• Sold $1,001 - $15,000 in shares of Vertiv NYSE: VRT on 11/27/2024.
• Purchased $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 11/26/2024.
• Purchased $1,001 - $15,000 in shares of Dominion Energy NYSE: D on 11/26/2024.
• Purchased $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 11/26/2024.
• Sold $1,001 - $15,000 in shares of Eaton NYSE: ETN on 11/25/2024.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 11/22/2024.
• Purchased $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 11/22/2024.

Natera Trading Up 1.6 %

Shares of NTRA traded up $2.63 on Friday, hitting $171.65. 814,477 shares of the stock traded hands, compared to its average volume of 1,620,024. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $22.66 billion, a P/E ratio of -97.53 and a beta of 1.63. The stock's 50 day moving average is $140.16 and its two-hundred day moving average is $122.53. Natera, Inc. has a 1 year low of $55.56 and a 1 year high of $175.63.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. As a group, sell-side analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group increased their price target on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. JPMorgan Chase & Co. increased their price target on shares of Natera from $135.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 13th. Sanford C. Bernstein increased their price target on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Stephens reissued an "overweight" rating and issued a $125.00 target price on shares of Natera in a research note on Friday, August 9th. Finally, StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $140.59.

Institutional Investors Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock worth $355,493,000 after acquiring an additional 1,883,481 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company's stock worth $483,034,000 after acquiring an additional 532,874 shares in the last quarter. AQR Capital Management LLC grew its holdings in Natera by 257.6% during the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company's stock worth $70,553,000 after acquiring an additional 469,327 shares in the last quarter. PointState Capital LP grew its holdings in Natera by 112.0% during the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company's stock worth $99,343,000 after acquiring an additional 413,468 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Natera by 53.6% during the 2nd quarter. Marshall Wace LLP now owns 958,383 shares of the medical research company's stock worth $103,783,000 after acquiring an additional 334,630 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $73,422.08. Following the completion of the transaction, the chief financial officer now directly owns 74,014 shares of the company's stock, valued at approximately $8,937,930.64. The trade was a 0.81 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. This represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,976 shares of company stock valued at $21,119,238 in the last ninety days. Corporate insiders own 7.60% of the company's stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer's career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer's committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.